GlassScriptPhysician profile
Mario Mejia
NPI 1518060664
$2,070.61
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,917 · 2024: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $154.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $499.21 | 2019 | |
| Novo Nordisk INC | $240.18 | 2019 | |
| Pfizer INC. | $223.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $185.79 | 2019 | |
| Dexcom, INC. | $154.03 | 2024 | Dexcom G7 Gss (161) |
| Avanir Pharmaceuticals, INC. | $153.90 | 2019 | |
| Amarin Pharma, INC. | $146.20 | 2019 | |
| Sanofi-Aventis U.S. LLC | $110.07 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $103.07 | 2019 | |
| Merck Sharp & Dohme LLC | $79.06 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.92 | 2019 | |
| Glaxosmithkline, LLC. | $30.32 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.31 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.49 | 2019 | |
| Amgen INC. | $12.73 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $12.42 | 2019 | |
| Daiichi Sankyo INC. | $12.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Mejia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.